Table 4 Descriptive analysis of treatment-related factors to time to survive of breast cancer
Variable | Category | Status | ||||
|---|---|---|---|---|---|---|
Survive | Death | |||||
Count | percent | Count | Percent | Total | ||
Baseline treatment | Surgery | 128 | 32.5% | 65 | 41.1% | 193(35%) |
Chemotherapy | 164 | 41.6% | 59 | 37.3% | 223(40.4%) | |
Surgery and chemotherapy | 102 | 25.9% | 34 | 21.5% | 136(24.6%) | |
Duration from date of diagnosis to surgery | < 30 | 254 | 64.5% | 101 | 63.9% | 355(64.3%) |
>=30 | 140 | 35.5% | 57 | 36.1% | 197(35.7%) | |
Adjuvant chemotherapy use | Yes | 128 | 32.5% | 63 | 39.9% | 193(34.6%) |
No | 266 | 67.5% | 95 | 60.1% | 361(65.4%) | |
Type of chemotherapy regimen | AC | 150 | 38.1% | 77 | 48.7% | 227(41.1%) |
Paclitaxel | 75 | 19.0% | 26 | 16.5% | 101(18.2%) | |
Combination | 169 | 42.9% | 55 | 34.8% | 224(40.5%) | |
Hormone therapy use | Yes | 320 | 81.2% | 132 | 83.5% | 452(82%) |
No | 74 | 18.8% | 26 | 16.5% | 100(18%) | |
Type of hormone used | Tamoxifen | 181 | 45.9% | 23 | 14.6% | 204(37%) |
Anastro zole | 213 | 54.1% | 135 | 85.4% | 348(63%) | |